SpyGlass Pharma (SGP) Stock Forecast: StockMap's 2-Week Call
SGP stock forecast: StockMap's model leans Underperform on SpyGlass Pharma for the two weeks after the Nov 19 close, toward SGP trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 6 two-week windows on SGP since Aug 21; by chance, a call on the same dates was right 58% of the time.
SpyGlass Pharma last closed at $30.78, +3.71% on the session.
Against the IVW growth benchmark the position is +6.04% over the forecast window.
SpyGlass Pharma's market cap is $1.03B as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -33 (too close to call).
Where SGP sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 1 bullish and 14 bearish.
Agreement across those insights is 93%.
46 daily calls for SGP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks SpyGlass Pharma in the 18th percentile on return on equity, where 100 is best.
SpyGlass Pharma is classified under Health Care / Pharmaceuticals.
StockMap tracks SpyGlass Pharma as the 64th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite SpyGlass Pharma ranks 75th of 153 in the group, against a group median of -0.36.